Botox Versus Tacrolimus in Psoriasis Vulgaris

Launched by ASSIUT UNIVERSITY · Jan 2, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two treatments for psoriasis vulgaris, a common skin condition that causes red, scaly patches on the skin. The study will look at how effective Botox and Tacrolimus are in helping patients with mild to moderate psoriasis. Psoriasis can significantly impact a person's quality of life, so finding effective treatments is very important.

To take part in the trial, patients should have a clinical diagnosis of mild to moderate psoriasis and must have stopped other systemic treatments or phototherapy for at least three months, and topical treatments for four weeks before joining. However, people with more severe forms of psoriasis, certain neurological conditions, or who are pregnant or breastfeeding cannot participate. The trial is not yet open for enrollment, but it aims to help improve treatment options for those living with psoriasis. Participants can expect to receive one of the two treatments and will be monitored for their response to therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with clinical diagnosis of mild to moderate psoriasis vulgaris
• • Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment.
• Exclusion Criteria:
• • • Psoriasis vulgaris involving \> 10% of the body surface area, pustular or erythrodermic psoriasis.
• • Patients with neuromuscular disease or history of epilepsy.
• • Pregnant or lactating females.
• • Patients with any current dermatological disease.
• • Patients with any current systemic disease.